Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Covington
Julphar
Baxter
Daiichi Sankyo
Cipla

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,747,498

« Back to Dashboard

Which drugs does patent 5,747,498 protect, and when does it expire?

Patent 5,747,498 protects TARCEVA and is included in one NDA.

Protection for TARCEVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-eight patent family members in forty-one countries.

Summary for Patent: 5,747,498
Title: Alkynyl and azido-substituted 4-anilinoquinazolines
Abstract:The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.
Inventor(s): Schnur; Rodney Caughren (Noank, CT), Arnold; Lee Daniel (Westborough, MA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:08/653,786
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,747,498
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 5,747,498
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Process;

Drugs Protected by US Patent 5,747,498

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-001 Nov 18, 2004 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-002 Nov 18, 2004 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-003 Nov 18, 2004 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 5,747,498

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 735 ➤ Sign Up
African Regional IP Organization (ARIPO) 9600788 ➤ Sign Up
Argentina 002723 ➤ Sign Up
Austria 205483 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Accenture
Chubb
Fish and Richardson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.